Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Argenx Se ( (ARGX) ) is now available.
On December 15, 2025, argenx SE announced the discontinuation of its Phase 3 UplighTED studies evaluating efgartigimod SC in adults with moderate to severe thyroid eye disease (TED) due to futility, as recommended by an Independent Data Monitoring Committee. Despite the trials not meeting desired outcomes, efgartigimod demonstrated a favorable safety profile. The company plans to conduct a comprehensive analysis of the data to gain insights for future research in TED. This decision reflects argenx’s commitment to responsible resource management in its clinical development programs.
The most recent analyst rating on (ARGX) stock is a Buy with a $1316.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
argenx is a global immunology company focused on developing novel antibody-based medicines to treat severe autoimmune diseases. Through partnerships with leading academic researchers, argenx aims to translate immunology breakthroughs into a world-class portfolio of therapies. The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, VYVGART, which is used for various autoimmune conditions.
Average Trading Volume: 351,919
Technical Sentiment Signal: Buy
Current Market Cap: $54.45B
Learn more about ARGX stock on TipRanks’ Stock Analysis page.